PE20081166A1 - Formulaciones liquidas de inhibidores de enzimas fosfolipasas - Google Patents
Formulaciones liquidas de inhibidores de enzimas fosfolipasasInfo
- Publication number
- PE20081166A1 PE20081166A1 PE2007001503A PE2007001503A PE20081166A1 PE 20081166 A1 PE20081166 A1 PE 20081166A1 PE 2007001503 A PE2007001503 A PE 2007001503A PE 2007001503 A PE2007001503 A PE 2007001503A PE 20081166 A1 PE20081166 A1 PE 20081166A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- composition
- weight
- furile
- pyridinyl
- Prior art date
Links
- 102000015439 Phospholipases Human genes 0.000 title abstract 2
- 108010064785 Phospholipases Proteins 0.000 title abstract 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 title 1
- 239000002532 enzyme inhibitor Substances 0.000 title 1
- 239000012669 liquid formulation Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 102100026918 Phospholipase A2 Human genes 0.000 abstract 1
- 101710096328 Phospholipase A2 Proteins 0.000 abstract 1
- 229920002675 Polyoxyl Polymers 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000004359 castor oil Substances 0.000 abstract 1
- 235000019438 castor oil Nutrition 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA LIQUIDA QUE COMPRENDE: A) UN SISTEMA PORTADOR O EXCIPIENTE QUE CONTIENE i) UN AGENTE TENSIOACTIVO TAL COMO ACEITE DE CASTOR POLIOXIL DE 50% A 90% EN PESO DE LA COMPOSICION Y ii) UN PROMOTOR DE LA BIODISPONIBILIDAD TAL COMO CAPRILOCAPROIL POLIOXIGLICERIDOS, POLIETILENGLICOLES, ENTRE OTROS, QUE SE ENCUENTRAN DE 10% A 30% EN PESO DE LA COMPOSICION; Y B) UN AGENTE FARMACOLOGICO DE FORMULA (I) QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,1% A 30% EN PESO DE LA COMPOSICION, EN DONDE R ES -(CH2)n-A, -(CH2)n-S-A Y -(CH2)n-O-A DONDE A ES UN COMPUESTO DE FORMULA (a) O (b), EN DONDE D ES ALQUILO(C1-C6), ALCOXI(C1-C6), CICLOALQUILO(C3-C6), ENTRE OTROS; B Y C SON CADA UNO FENILO, PIRIDINILO, FURILO, ENTRE OTROS; n ES DE 0 A 3; n1 ES DE 1 A 3; n2 ES DE 0 A 4; n3 ES DE 0 A 3; X1 ES UN ENLACE, O, S, S(O), ENTRE OTROS; R1 ES ALQUILO(C1-C6), ALQUILO(C1-C6)FLUORADO, CICLOALQUILO(C3-C6), ENTRE OTROS; X2 ES O, CH2, S, SO, ENTRE OTROS; R2 ES FENILO, PIRIDINILO, FURILO, ENTRE OTROS; R3 ES H, HALOGENO, CN, CF3, ENTRE OTROS; R4 ES H, HALOGENO, CHO, OH, ENTRE OTROS; R5 ES H O ALQUILO(C1-C3); R6 ES H O ALQUILO(C1-C6); SIENDO UN COMPUESTO PREFERIDO EL ACIDO 4-(3-{5-CLORO-1-(DIFENILMETIL)-2-[2-({[2(TRIFLUOROMETIL)BENCIL]SULFONIL}AMINO)ETIL]-1H-INDOL-3-IL}PROPIL)BENZOICO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE ENZIMAS FOSFOLIPASAS TALES COMO LAS ENZIMAS CITOSOLICAS PLA2 SIENDO UTILES COMO ANTIINFLAMATORIOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85557006P | 2006-10-31 | 2006-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081166A1 true PE20081166A1 (es) | 2008-10-06 |
Family
ID=39345041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001503A PE20081166A1 (es) | 2006-10-31 | 2007-10-31 | Formulaciones liquidas de inhibidores de enzimas fosfolipasas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100069385A1 (es) |
| EP (1) | EP2077825A2 (es) |
| JP (1) | JP2010508303A (es) |
| AR (1) | AR063745A1 (es) |
| AU (1) | AU2007313711A1 (es) |
| BR (1) | BRPI0718066A2 (es) |
| CL (1) | CL2007003144A1 (es) |
| PE (1) | PE20081166A1 (es) |
| TW (1) | TW200829549A (es) |
| WO (1) | WO2008055141A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012031763A1 (en) | 2010-09-08 | 2012-03-15 | Twincore Zentrum Fuer Experimentelle Und Klinische Infektionsforschung Gmbh | Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6797708B2 (en) * | 2001-12-03 | 2004-09-28 | Wyeth | Inhibitors of cytosolic phospholipase A2 |
| US7605156B2 (en) * | 2001-12-03 | 2009-10-20 | Wyeth | Methods for the use of inhibitors of cytosolic phospholipase A2 |
| PL370445A1 (en) * | 2001-12-03 | 2005-05-30 | Wyeth | Inhibitors of cytosolic phospholipase a2 |
-
2007
- 2007-10-30 TW TW096140779A patent/TW200829549A/zh unknown
- 2007-10-30 CL CL200703144A patent/CL2007003144A1/es unknown
- 2007-10-30 US US12/513,046 patent/US20100069385A1/en not_active Abandoned
- 2007-10-30 BR BRPI0718066-7A patent/BRPI0718066A2/pt not_active Application Discontinuation
- 2007-10-30 WO PCT/US2007/082975 patent/WO2008055141A2/en not_active Ceased
- 2007-10-30 EP EP07868614A patent/EP2077825A2/en not_active Withdrawn
- 2007-10-30 JP JP2009534935A patent/JP2010508303A/ja not_active Withdrawn
- 2007-10-30 AU AU2007313711A patent/AU2007313711A1/en not_active Abandoned
- 2007-10-31 AR ARP070104831A patent/AR063745A1/es unknown
- 2007-10-31 PE PE2007001503A patent/PE20081166A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200829549A (en) | 2008-07-16 |
| JP2010508303A (ja) | 2010-03-18 |
| US20100069385A1 (en) | 2010-03-18 |
| BRPI0718066A2 (pt) | 2013-11-05 |
| WO2008055141A2 (en) | 2008-05-08 |
| WO2008055141A3 (en) | 2009-03-12 |
| AR063745A1 (es) | 2009-02-18 |
| AU2007313711A1 (en) | 2008-05-08 |
| CL2007003144A1 (es) | 2008-06-20 |
| EP2077825A2 (en) | 2009-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
| PE20121437A1 (es) | Compuestos de espiropiperidina y uso farmaceutico de los mismos para el tratamiento de diabetes | |
| PE20090815A1 (es) | Compuesto de amida | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20040892A1 (es) | Antagonistas del receptor muscarinico m3 de acetilcolina | |
| PE20091816A1 (es) | Inhibidores de bace | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| PE20080552A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
| PE20141700A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido) pirimidina | |
| CO6140053A2 (es) | Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas | |
| ES2655391T3 (es) | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa | |
| PE20050948A1 (es) | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv | |
| AR074676A1 (es) | Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa. | |
| PE20120062A1 (es) | Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1 | |
| PE20130382A1 (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| PE20110368A1 (es) | Moduladores de mif | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| PE20080267A1 (es) | Compuestos triarilicos y sus derivados | |
| PE20120261A1 (es) | Piperidina espiro pirrolidinona y piperidinonas sustitudos como moduladores de los receptores h3 | |
| AR055563A1 (es) | Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente | |
| PE20090243A1 (es) | Compuestos de imidazol sustituido como inhibidores de renina | |
| PE20080364A1 (es) | Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa | |
| AR057072A1 (es) | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto | |
| MY161403A (en) | 5- (phenyl/pyridinyl-ethinyl) -2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |